Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Holding NEO?
Track your performance easily
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.13 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)1.00M
Market Cap
$1.79B
Enterprise Value$2.09B
Total Cash (Recent Filing)$12.53M
Total Debt (Recent Filing)$97.44M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Feb 25, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding128,360,870
10 Day Avg. Volume1,541,318
30 Day Avg. Volume1,000,328
Standard Deviation0.17
R-Squared0.14
Alpha-0.00939
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.79
Price to Cash Flow (P/CF)48.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue3.25
Enterprise Value/Gross Profit8.55
Enterprise Value/Ebitda5.18K
Forecast
1Y Price Target
$19.33Price Target Upside36.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
NeoGenomics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNeoGenomics has achieved eight consecutive quarters of double-digit revenue growth and consistent increases in average revenue per test.
Product DevelopmentNeoGenomics plans to launch new products like PanTracer LBx for clinical use, with further developments in solid tumor diagnostics anticipated to enhance market penetration.
Revenue GuidanceNEO provided 2025 revenue guidance of $735-745M, which is above the consensus estimate of $728M.
Bears Say
Advanced Diagnostics PerformanceAdvanced Diagnostics saw a 10% decline year-over-year, driven by lower revenues from RaDaR, international site closures, and restructuring.
Management ChangesThe unexpected announcement of CEO Chris Smith's retirement has led to a significant drop in share price and raised concerns about potential further management departures.
Stock ValuationThe progress in revamping NeoGenomics' core business is largely priced into the shares, limiting potential upside.
---
Ownership Overview
1.13% Insiders
35.77% Mutual Funds
0.10% Other Institutional Investors
37.34% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $12.13 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.79B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Feb 25, 2025 which is in 38 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Nov 05, 2024. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.012 by $0.038.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.03.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,360,870 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.05 in its last earnings report, beating expectations of $0.012. Following the earnings report the stock price went up 5.587%.
Which hedge fund is a major shareholder of NeoGenomics?
Among the largest hedge funds holding NeoGenomics’s share is Royce & Associates LLC. It holds NeoGenomics’s shares valued at 9M.
---
NeoGenomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.33 (36.03% Upside)
$19.33 (36.03% Upside)
Hedge Fund Trend
Increased
By 376.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.08%
12-Months-Change
Fundamentals
Return on Equity
-8.38%
Trailing 12-Months
Asset Growth
-2.21%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
---
NEO Company Deck
---
NEO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved profitability, and successful product launches. However, challenges such as a decline in Pharma revenue and increased legal expenses were noted. Overall, the company's financial performance and strategic initiatives indicate a positive outlook.Read More>---
NEO Stock 12 Month Forecast
Average Price Target
$19.33
▲(36.03% Upside)
Technical Analysis
Best Analysts Covering NEO
1 Year
1 Year Success Rate
6/24 ratings generated profit
1 Year Average Return
-10.61%
reiterated a buy rating 4 days ago
Copying Puneet Souda's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -10.61% per trade.
---